Shanghai Haohai Biological Technology Co., Ltd. (6826.HK)
HKD 26.85
(-1.65%)
HKD 26.85
(-1.65%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.1 Billion CNY | 3.09% |
| 2022 | 6.89 Billion CNY | -0.83% |
| 2021 | 6.95 Billion CNY | 10.35% |
| 2020 | 6.29 Billion CNY | 2.39% |
| 2019 | 6.15 Billion CNY | 38.67% |
| 2018 | 4.43 Billion CNY | 8.86% |
| 2017 | 4.07 Billion CNY | 10.34% |
| 2016 | 3.69 Billion CNY | 30.88% |
| 2015 | 2.82 Billion CNY | 275.3% |
| 2014 | 751.9 Million CNY | 21.04% |
| 2013 | 621.17 Million CNY | 38.64% |
| 2012 | 448.03 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 7.24 Billion CNY | 0.68% |
| 2024 Q1 | 7.19 Billion CNY | 1.23% |
| 2023 Q3 | 7.08 Billion CNY | -2.27% |
| 2023 FY | 7.1 Billion CNY | 3.09% |
| 2023 Q1 | 7.25 Billion CNY | 5.25% |
| 2023 Q2 | 7.25 Billion CNY | 0.0% |
| 2023 Q4 | 7.1 Billion CNY | 0.23% |
| 2022 Q4 | 6.89 Billion CNY | 0.0% |
| 2022 Q3 | 6.89 Billion CNY | -1.75% |
| 2022 Q2 | 7.01 Billion CNY | 0.0% |
| 2022 Q1 | 7.01 Billion CNY | 0.93% |
| 2022 FY | 6.89 Billion CNY | -0.83% |
| 2021 Q1 | 6.59 Billion CNY | 4.73% |
| 2021 Q2 | 6.59 Billion CNY | 0.0% |
| 2021 Q3 | 6.81 Billion CNY | 3.26% |
| 2021 Q4 | 6.95 Billion CNY | 2.04% |
| 2021 FY | 6.95 Billion CNY | 10.35% |
| 2020 Q3 | 6.14 Billion CNY | -0.54% |
| 2020 FY | 6.29 Billion CNY | 2.39% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 6.29 Billion CNY | 2.5% |
| 2020 Q2 | 6.17 Billion CNY | 0.0% |
| 2019 Q4 | 6.15 Billion CNY | 0.0% |
| 2019 FY | 6.15 Billion CNY | 38.67% |
| 2019 Q2 | 4.46 Billion CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q2 | 4.22 Billion CNY | 0.0% |
| 2018 Q4 | 4.43 Billion CNY | 0.0% |
| 2018 Q1 | 4.22 Billion CNY | 3.74% |
| 2018 Q3 | 4.43 Billion CNY | 4.94% |
| 2018 FY | 4.43 Billion CNY | 8.86% |
| 2017 Q3 | 4.1 Billion CNY | 7.07% |
| 2017 FY | 4.07 Billion CNY | 10.34% |
| 2017 Q1 | 3.83 Billion CNY | 3.92% |
| 2017 Q2 | 3.83 Billion CNY | 0.0% |
| 2017 Q4 | 4.07 Billion CNY | -0.83% |
| 2016 Q1 | 2.93 Billion CNY | 3.84% |
| 2016 Q3 | 3.69 Billion CNY | 26.04% |
| 2016 Q2 | 2.93 Billion CNY | 0.0% |
| 2016 FY | 3.69 Billion CNY | 30.88% |
| 2016 Q4 | 3.69 Billion CNY | 0.0% |
| 2015 Q3 | 2.82 Billion CNY | 5.53% |
| 2015 Q2 | 2.67 Billion CNY | 0.0% |
| 2015 Q1 | 2.67 Billion CNY | 255.63% |
| 2015 FY | 2.82 Billion CNY | 275.3% |
| 2015 Q4 | 2.82 Billion CNY | 0.0% |
| 2014 Q1 | 725.81 Million CNY | 16.84% |
| 2014 FY | 751.9 Million CNY | 21.04% |
| 2014 Q3 | 751.9 Million CNY | 3.59% |
| 2014 Q2 | 725.81 Million CNY | 0.0% |
| 2014 Q4 | 751.9 Million CNY | 0.0% |
| 2013 Q3 | 621.17 Million CNY | 0.0% |
| 2013 Q4 | 621.17 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | 621.17 Million CNY | 38.64% |
| 2012 FY | 448.03 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 409.99 Million HKD | -1633.082% |
| CK Life Sciences Int'l., (Holdings) Inc. | 11.24 Billion HKD | 36.825% |